Mats Grahn, Chief Executive Officer
Mats holds a MSc in Engineering Physics from Lund University, Sweden. He brings more than 25 years experiences in senior leading positions within the life science and diagnostics industry. He contributes with an extensive experience in business and strategic development, marketing, product management, product development and market access. Mats has a track record of leading international commercial operational organizations, restructuring of marketing organizations, integration of acquired companies as well as managing new start-ups. Much of his experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Previous positions include CVP Marketing Dako A/S, VP Product Management GE Healthcare, VP Marketing Amersham Biosciences, VP Laboratory Separations Pharmacia Biotech and VP Prevas Bioinformatics.
Current appointments: Chairman of the Board and CEO of Gusmo AB. Deputy Director of Utas Glassmakeri AB.
Completed appointments (last five years): Chairman of the Board of Alligator Bioscience AB, Atlas Therapeutics AB och Bmatrix AB. Leading positions at Spiber Technologies AB and Biocrine AB.
Rolf Ehrnström, Chief Scientific Officer
Rolf holds a MSc in biochemistry & biotechnology engineering from Royal Institute of Technology, Stockholm, Sweden. Rolf is the owner of Reomics AB and an independent partner at Ventac Partners. He has long experience of leading research and has been a Corporate Vice President R&D and Chief Scientific Officer at Dako/Agilent and Gyros AB. Rolf has also experience as a Science Director at Amersham Pharmacia Biotech.
Current appointments: Board Member of Reomics AB sand Fluimedix A/S Danmark. Member of the Nomination Committee of Idogen AB.
Completed appointments (last five years): Board Member of Biomonitor A/S.
Peter Schulz-Knappe, Chief Technology Officer
Peter holds a MD in medicine and a PhD in cellular biology from Heidelberg University, Germany. He has been in biotechnology and proteomics for over 25 years, as serial entrepreneur, mainly as CSO and CTO of biotech companies. His focus is the discovery and development of diagnostic signatures from human blood. He has developed several high throughput platforms for mass spectrometry based peptide and protein analysis as well as protein arrays.
Peter founded BioVisioN AG in Germany where he developed peptidomics workflows, was CSO at Proteome Sciences in UK (quantitative mass spectrometry) and CSO at Protagen in Germany (protein arrays for autoimmune diseases and immuno-oncology). He led multiple clinical trials with international research organizations and pharma companies to develop novel diagnostics and companion diagnostics.
Current appointments: None
Completed appointments (last five years): CSO, Protagen AG, Germany
Hans Liljenborg, Chief Financial Officer
Hans Liljenborg has a degree as subject teacher in Business Administration and Mathematics from Lund University, Sweden. Hans has long experience as Financial Manager for growing, global medical technology companies and has been Finance Director at Physio Control Inc, Jolife AB and Finance Manager at Vivoline Medical AB, listed on Nasdaq First North in March 2015. He also operates an own accounting firm.
Current appointments: Board Member of ADAYS AB. Deputy Director of Entreprenörskompetens i Lund AB, Gantus Training AB and IES Interactive Executive Search AB. Auditor at Personalkooperativet Byns Förskola Ekonomisk förening. Holder of Prosperus.
Completed appointments (last five years): Leading positions at E-vård MinDoktor.se Sverige AB, Jolife AB, Quick-Cool AB and Vivoline Medical AB. Auditor at Bostadsrättsföreningen Långgårdsgatan 17 and Solbacka Trading.
Laura Chirica, Chief Commercial Officer
Laura holds a PhD in Biochemistry from Umeå University, Sweden, a MSc in Biochemistry and a BSc in Biotechnology. With more than 15 years experiences in leading commercial positions within the life science and diagnostics industry, Laura contributes with an extensive experience in business, organization and strategic development, sales, strategic and tactical marketing, product management and product support. She has a track record of leading and restructuring international sales and marketing organizations, driving business development, champion integration of acquired companies as well as developing branding and market communication platforms. Much of her experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Previous positions include VP Sales and Marketing Euro Diagnostica AB, Director Purification Technologies Europe Sartorius Stedim, Global Marketing Director Dako A/S, and Global Marketing Program Manager GE Healthcare.
Current appointments: Board Member of SenzaGen AB.
Completed appointments (last five years): Leading position at Euro-Diagnostica AB.
Henrik Winther, SVP Business Development
Henrik holds a DVM and PhD in cell biology and histology from University of Copenhagen. He has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products. From 2006, Henrik was R&D Director at Dako A/S and spearheaded the design responsibility of their most successful product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies. Previous positions include VP and General Manager at Agilent in Santa Barbara, CA – as well as head of the R&D function – of the Companion Diagnostics Division. He has earlier worked as an Associate Professor within cell biology, but during the last 17 years focused on cancer diagnostics.
Current appointments: Board Member of Saga Diagnostics AB.
Completed appointments (last five years): Leading positions at Agilent Technologies and Dako A/S.
Linda Mellby, VP Research & Development
Linda received her PhD in Immunotechnology from Dept. of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, in 2010, and a MSc in Chemistry Engineering in 2004. Linda has more than 15 year’s experiences of recombinant antibody microarray technology, the Immunovia platform. She has deep knowledge about platform features, technology development as well as clinical applications within oncoproteomics and autoimmunity. She has been one of the key researchers managing the development of the Immunovia antibody microarray platform for disease proteomics, conducting extensive work related to process optimizations, standardizations as well as clinical studies.
Current appointments: None
Completed appointments (last five years): None
Lotta Blomgren, Operations Director
Lotta holds a MSc in Chemical Engineering from Lund University, Sweden. Lotta has more than 30 years’ experience within the life science and diagnostics industry, whereof 15 years in leading positions. She contributes with extensive experience from leading manufacturing, quality control and logistics teams, as well as managing transfer of new products from development to commercial scale. Her track record includes strategic reorganizations of international manufacturing networks, managing people and project portfolios, as well as due diligence of potential acquirement of new companies and Contract Manufacturing (CMO).
Previous positions include VP Technical Operations at Euro Diagnostica AB, Head of Supply Chain Bioglan AB, Director Product & Technology Support Ferring A/S, Head of Process Development Ferring AB, cross functional roles within Process Development and Project Management at Astra AB, Kabi Pharmacia AB and ACO AB.
Current appointments: None
Completed appointments (last five years): Leading positions at Bioglan AB and EuroDiagnostica AB.